-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Finishingrainbow
Yesterday (June 28), Shanxi Pharmaceutical Equipment Centralized Bidding and Purchasing Network issued a notice showing that the "Drug Business License" of GlaxoSmithKline (China) Investment Co.
Screenshot from Shanxi Province Pharmaceutical Equipment Centralized Bidding Purchasing Network
GlaxoSmithKline (GSK)'s move in China echoes its global strategy of accelerating transformation
In recent years, GSK’s performance can be said to have been "declining steadily", which may be an important reason why the company has proposed an accelerated transformation strategy this year
In a statement, GSK stated that “through the divestiture of non-priority products, it will focus on supporting vaccines and special drugs
Reference source: E medicine manager, Health and Knowledge Bureau